Nautilus Biotechnology is trading 5.12% higher at $2.15 as of 12:49 p.m. ET on October 14, 2026, with no confirmed company-specific catalyst identified.
- The latest item about its Voyager commercial strategy dates to October 1, not October 14.
- The broader backdrop is risk-off: September inflation exceeded expectations and pressured growth-sensitive stocks, while biotech shares were also weak; neither explains Nautilus Biotechnology’s gain.
- No reliable volume figure was available in the supplied price context.